Hematology 2006
© 2006 The American Society of Hematology
Management of Hereditary Hypercoagulable Disorders
Paula L. Bockenstedt
Correspondence: Paula Bockenstedt, MD, University of Michican, 200 Barton N Drive, Ann Arbor MI 48105; Phone 734-647-3124; Fax 734-764-0101; Email pbockens{at}umich.edu
Abstract
The clinical management of individuals with hereditary hypercoaguable disorders has evolved from initial broad recommendations of lifelong anticoagulation after first event of venous thromboembolism to a more intricate individualized risk-benefit analysis as studies have begun to delineate the complexity of interactions of acquired and hereditary factors which determine the predilection to thrombosis. The contribution of thrombophilic disorders to risk of thrombotic complications of pregnancy, organ transplantation, central venous catheter and dialysis access placement have been increasingly recognized. The risk of thrombosis must be weighed against risk of long-term anticoagulation in patients with venous thromboembolism. Thrombophilia screening in select populations may enhance outcome.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Copyright © 2006 by the American Society of Hematology.
